Clinical-stage biopharmaceutical company developing antibody-drug conjugates for cancer.
Mersana Therapeutics, Inc. is a clinical-stage biopharmaceutical company dedicated to advancing the field of cancer treatment through innovative antibody drug conjugates (ADCs). These specialized therapies are designed to address critical unmet needs among cancer patients. One of its key developments is XMT-1592, an ADC known as Dolasynthen, which targets NaPi2b-expressing tumor cells. Currently in phase I clinical trials, XMT-1592 shows promise for treating ovarian cancer and NSCLC adenocarcinoma.
In addition to XMT-1592, Mersana Therapeutics is actively progressing other ADC candidates. These include XMT-1660, which targets B7-H4 using the Dolasynthen platform, and XMT-2056, an immunosynthen development candidate. These initiatives underscore the company's commitment to leveraging advanced technologies to broaden treatment options for cancer patients.
Mersana Therapeutics collaborates closely with industry leaders to enhance its ADC pipeline. Notably, strategic research and development partnerships with Merck KGaA and Asana BioSciences, LLC focus on utilizing Fleximer, a proprietary polymer technology, to develop novel ADC product candidates. These collaborations highlight Mersana's strategy of combining expertise and resources to drive innovation in cancer therapy.
Founded in 2001 and headquartered in Cambridge, Massachusetts, Mersana Therapeutics, Inc. originally operated under the name Nanopharma Corp. before rebranding in November 2005. The company continues to pioneer advancements in biopharmaceuticals, striving to transform the treatment landscape for cancer patients worldwide.